

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex:

Female

Specimen Collected: 12-Mar-24 14:50**IDH1 R132H Point Mutation by IHC | Received: 12-Mar-24 14:56****Report/Verified: 13-Mar-24 10:54****w/Rflx**

Procedure	Result	Units	Reference Interval
IDH1 R132H Point Mut by IHC with Reflex	Positive ⁱ¹		
IDH1 Tissue Source	L Frontal Brain		
IDH1 R132H Mutation Reference Number	B-27		

Test Information

i1: IDH1 R132H Point Mut by IHC with Reflex

INTERPRETIVE INFORMATION: IDH1 R132H Point Mut by IHC
with Reflex

IDH1 R132H Point Mutation by Immunohistochemistry detects the presence of mutant IDH1 R132H protein expression in diffuse gliomas and can serve as a screening tool for molecular testing. A positive result indicates a probable IDH1 R132H mutation. A negative result indicates the tumor has no R132H mutation, which will automatically reflex to IDH1 and IDH2 gene sequencing, to detect less common IDH1 or IDH2 mutations not detected by the IHC test. This test is performed on paraffin-embedded, formalin-fixed tissue.

Controls were run and performed as expected.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

* = Abnormal, # = Corrected, C = Critical, f = Result Footnote, H = High, i = Test Information, L = Low, t = Interpretive Text, @ = Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-072-900199**Report Request ID:** 19129207**Printed:** 13-Mar-24 12:51

Page 1 of 1